OBJECTIVE: Patients with acute coronary syndrome without ST-segment elevation receiving Clopidogrel in addition to acetylsalicylic acid (ASS) showed 20% risk reduction in the CURE trial. Economic models for assessing the impact on costs exist for several countries, however not for Germany on a long-term basis. The objective of this model adaptation is to assess the long-term economic impact of Clopidogrel taken in addition to ASS in Germany. METHODS: A Markov model with six states (at risk, first year with stroke, following years with stroke, first year with new myocardial infarction (MI), following years with MI and death) was adapted for Germany. Model outcome was life-years saved. Cost and effects of one year treatment were calculated based on the CURE trial. Resource use for the different health states during follow-up were based on desk research or on expert opinion, which included costs for drugs, physician visits, hospitalisation,rehabilitation and nursing. Risk data for MI and stroke were based on Swedish data. The model calclulates life-time costs and survival length. Costs were estimated from the payers’l perspective within the German health care system. Sensitivity analysis varied follow-up treatment costs at –50% and +100%. RESULTS: The Markov analysis resulted in 8.89 life-years saved for the placebo treatment group and 9.02 for the Clopidogrel® treatment group. The cumulated cost were 9288 and 9653 resp. The incremental cost effectiveness ratio (ICER) was 2670€ for each life-years saved. In the sensitivity analysis halving of follow-up cost lead to an ICER at 3666€ and doubling to 677€. CONCLUSION: Our results are in line with results in other healthcare systems. Adding Clopidogrel in addition to ASS for patients with acute coronary syndrome without ST-segment elevation generates an additional life-year saved at a comparably low value of 2670€ in Germany.